CSTL icon

Castle Biosciences

22.53 USD
+0.02
0.09%
At close Updated Oct 16, 4:00 PM EDT
Pre-market
After hours
22.53
0.00
0%
1 day
0.09%
5 days
-5.42%
1 month
3.59%
3 months
20.61%
6 months
5.97%
Year to date
-19.65%
1 year
-33.28%
5 years
-54.91%
10 years
5.28%
 

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Employees: 798

0
Funds holding %
of 7,495 funds
0
Analysts bullish %
of 1 analysts
0
Positive news %
of 4 articles
Price charts implemented using Lightweight Charts™